Zoetis Inc. (NYSE:ZTS) Shares Purchased by Fortitude Family Office LLC

Fortitude Family Office LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 1,387.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 238 shares of the company’s stock after acquiring an additional 222 shares during the period. Fortitude Family Office LLC’s holdings in Zoetis were worth $46,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Quarry LP grew its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. LRI Investments LLC bought a new position in shares of Zoetis during the first quarter worth about $43,000. Central Valley Advisors LLC acquired a new stake in shares of Zoetis in the 2nd quarter worth about $49,000. Future Financial Wealth Managment LLC acquired a new position in Zoetis during the 3rd quarter valued at about $59,000. Finally, EdgeRock Capital LLC bought a new stake in shares of Zoetis during the second quarter valued at approximately $56,000. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.8 %

Zoetis stock opened at $181.27 on Wednesday. The firm has a market cap of $82.12 billion, a price-to-earnings ratio of 34.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s 50 day moving average price is $189.02 and its two-hundred day moving average price is $178.25. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.41 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.14%.

Analyst Ratings Changes

Several research firms recently commented on ZTS. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.